Plain-English translation of NCT07080021 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is tracking a blood test called circulating tumor DNA (ctDNA) in patients with pancreatic cancer who are receiving chemotherapy before surgery. Researchers want to understand whether this blood test can predict whether surgery will be successful and how long patients will survive. The hope is that this test could help doctors decide how long each patient should receive chemotherapy before surgery.
Pancreatic cancer is serious, and doctors currently have limited ways to know whether pre-surgery chemotherapy is working well enough or how long treatment should last. This blood test might offer a new, non-invasive way to monitor whether the treatment is helping and guide decisions about when patients are ready for surgery.
You likely qualify if…
You likely don't qualify if…
You will receive 4 to 8 cycles of chemotherapy before surgery, as determined by your doctors following standard treatment guidelines. During this time, you will have blood samples taken multiple times to measure the cancer markers in your blood. After your tumor tissue is sampled (either before chemotherapy starts or during the first cycle), you will continue with your regular chemotherapy and then proceed to surgery as planned. The entire study participation lasts about 18 months, including 12 months of treatment and monitoring followed by 6 months of follow-up visits.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China